Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
staphylococcus albus bacterial lysate
- Development stage
- Unknown
- Lead developer
- Qingdao Center Hospital
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Staphylococcus albus bacterial lysate is an immunomodulatory biologic agent derived from the lysis of *Staphylococcus albus* (now taxonomically classified as *Staphylococcus epidermidis*). It is primarily utilized as an oral immunostimulant for the prevention and adjunctive treatment of recurrent respiratory tract infections and chronic obstructive pulmonary disease (COPD). The lysate functions by presenting bacterial antigens to the gut-associated lymphoid tissue (GALT) and mucosal-associated lymphoid tissue (MALT), which enhances the production of secretory IgA (SIgA), activates macrophages, and modulates T-lymphocyte activity. Clinical research, including studies conducted at Qingdao Municipal Hospital, has investigated its role in stabilizing airway and gut microbiota and influencing mitochondrial autophagy-related markers to improve lung function in patients with stable COPD.
- Other names
- staphylococcus albus bacterial lysatestaphylococcus albus lysatestaphylococcus epidermidis bacterial lysate
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on staphylococcus albus bacterial lysate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on staphylococcus albus bacterial lysate.